Received Apr 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | U8660AC | — |
got the first dose of MENQUADFI when they were 12 years old and received a 2nd dose at 15 years old with no AE; Initial information received on 01-Apr-2026 regarding an unsolicited valid non-serious case received from a healthcare professional (HCP). This case involves a 15-year-old male patient who got the first dose of Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi] when he was 12 years old and received a 2nd dose at 15 years old with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s), family history, concomitant medications were not provided. On 12-Mar-2026, the patient received an unknown dose (dose 2) Meningococcal A-C-Y-W135 (T Conj) Vaccine, Solution for injection (batch: U8660AC, expiry date: 2029-03-31) (strength: unknown) via unknown route and unknown administration site for Immunization. The patient got the first dose of Menquadfi when he was 12 years old and received a 2nd dose at 15 years old with no adverse event [(Product administered to patient of inappropriate age, onset: 12-Mar-2026 and latency: same day) (batch: U8660AC, expiry date: 2029-03-31)]. Action taken: unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE